Literature DB >> 6453556

Cefoperazone concentrations in bile and gall bladder wall after intravenous administration.

T Nakamura, I Hashimoto, Y Sawada, J Mikami, E Bekki, S Hirasawa, H Abe, Y Watanabe.   

Abstract

Cefoperazone concentrations in the common duct bile, gall bladder bile, and gall bladder wall were determined in four patients with cholelithiasis and one patient with carcinoma of the head of the pancreas, all of whom had normal renal functions. Within 65 min after a 1-g intravenous administration, maximum concentrations ranged from 373.4 to 3,100 micrograms/ml in common duct bile and from 6.8 to 680 micrograms/ml in gall bladder bile. Cefoperazone concentrations per gram of the gall bladder wall ranged from 16.8 to 48.0 micrograms.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6453556      PMCID: PMC353002          DOI: 10.1128/AAC.18.6.980

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  1 in total

1.  Biliary tract excretion of cefazolin, cephalothin, and cephaloridine in the presence of biliary tract disease.

Authors:  K R Ratzan; C Ruiz; G L Irvin
Journal:  Antimicrob Agents Chemother       Date:  1974-10       Impact factor: 5.191

  1 in total
  13 in total

1.  Penetration of ceftriaxone and cefoperazone into bile and gallbladder tissue in patients with acute cholecystitis.

Authors:  R Orda; S A Berger; Y Levy; A Shnaker; A Gorea
Journal:  Dig Dis Sci       Date:  1992-11       Impact factor: 3.199

2.  Penetration of cefazolin, ceftriaxone, cefoperazone, and ceftazidime into human gallbladder tissue and bile.

Authors:  S A Berger; Y Levy; A Halevy; A Gorea; R Orda
Journal:  World J Surg       Date:  1988-10       Impact factor: 3.352

Review 3.  Classification of cephalosporins.

Authors:  J D Williams
Journal:  Drugs       Date:  1987       Impact factor: 9.546

4.  Comparative pharmacokinetics of cefoperazone, cefotaxime, and moxalactam.

Authors:  B Kemmerich; H Lode; G Belmega; T Jendroschek; K Borner; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1983-03       Impact factor: 5.191

5.  Cefoperazone compared with ampicillin plus tobramycin for severe biliary tract infections.

Authors:  M G Bergeron; J Mendelson; G K Harding; L Mandell; I W Fong; A Rachlis; R Chan; S Biron; R Feld; N B Segal
Journal:  Antimicrob Agents Chemother       Date:  1988-08       Impact factor: 5.191

6.  The influence of third-generation cephalosporins on the aerobic intestinal flora.

Authors:  J P Guggenbichler; J Kofler; F Allerberger
Journal:  Infection       Date:  1985       Impact factor: 3.553

7.  Biliary levels of ceforanide.

Authors:  D E Kenady; M D Ram
Journal:  Antimicrob Agents Chemother       Date:  1983-05       Impact factor: 5.191

8.  Antimicrobial activity and other in vitro properties of cefoperazone A, the principal metabolite of cefoperazone sodium.

Authors:  R N Jones; A L Barry
Journal:  Antimicrob Agents Chemother       Date:  1983-08       Impact factor: 5.191

9.  Impact of cefoperazone therapy on fecal flora.

Authors:  M E Mulligan; D M Citron; B T McNamara; S M Finegold
Journal:  Antimicrob Agents Chemother       Date:  1982-08       Impact factor: 5.191

10.  Effect of ursodeoxycholate on the biliary excretion of cefotiam and sulbenicillin in patients with percutaneous transhepatic biliary drainage.

Authors:  K Higashi; T Hayakawa; K Katagiri; K Tsukada; K Ito; M Hoshino; M Miyaji; T Takeuchi; T Yamamoto
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.